Latest Non-Hodgkin lymphoma Stories
Researchers at the University of Maryland School of Medicine have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma.
Researchers from the University of Sheffield have discovered valuable insight into how people develop B-cell lymphoma, one of the most common cancers in the UK.
Researchers at North Carolina State University are narrowing the search for genes involved in non-Hodgkin lymphoma â€“ by turning dogs into humans.
SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc.
ORLANDO, Fla. and SUNNYVALE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc.
SEATTLE, Nov. 18, 2010 /PRNewswire/ -- Cell Therapeutics, Inc.
Long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, but was associated with lowering risk of melanoma, endometrial cancer and non-Hodgkin lymphoma.
Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults.
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma.
NEW YORK, Sept. 21 /PRNewswire/ -- While general awareness of lymphoma remains high, a new survey released today by the Lymphoma Research Foundation (LRF) reveals significant knowledge gaps among Americans about the disease, which is the most prevalent form of blood cancer in the United States.